Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Uterine cancer, mutational phenotype, and the era of immune checkpoint blockade.

Roque DM, Santin AD.

Expert Rev Clin Immunol. 2017 Mar;13(3):175-180. doi: 10.1080/1744666X.2017.1266938. Epub 2016 Dec 12. No abstract available.

PMID:
27905822
2.

Biventricular metastatic invasion from cervical squamous cell carcinoma.

Kapoor K, Evans MC, Shkullaku M, Schillinger R, White CS, Roque DM.

BMJ Case Rep. 2016 Jul 1;2016. pii: bcr2016214931. doi: 10.1136/bcr-2016-214931.

PMID:
27371746
3.

Oncofertility in gynecologic oncology: an oxymoron?

Roque DM, Santin AD.

Future Oncol. 2016 Jul;12(14):1683-6. doi: 10.2217/fon-2016-0167. Epub 2016 May 13. No abstract available.

PMID:
27173792
4.

Risk, risk reduction and management of occult malignancy diagnosed after uterine morcellation: a commentary.

Lynam S, Young L, Morozov V, Rao G, Roque DM.

Womens Health (Lond). 2015 Nov;11(6):929-44. doi: 10.2217/whe.15.63. Epub 2015 Dec 17.

PMID:
26673851
5.

Reply: To PMID 25577672.

Santin AD, Roque DM.

Am J Obstet Gynecol. 2015 Dec;213(6):881. doi: 10.1016/j.ajog.2015.08.029. Epub 2015 Aug 17. No abstract available.

PMID:
26292047
6.

Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.

Roque DM, Ratner ES, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Nelson WK, Santin AD.

Gynecol Oncol. 2015 Jun;137(3):392-400. doi: 10.1016/j.ygyno.2015.03.008. Epub 2015 Mar 17. Review.

PMID:
25792179
7.

A series of malignant ovarian cancers arising from within a mature cystic teratoma: a single institution experience.

Black JD, Roque DM, Pasternak MC, Buza N, Rutherford TJ, Schwartz PE, McCarthy S, Ratner E.

Int J Gynecol Cancer. 2015 Jun;25(5):792-7. doi: 10.1097/IGC.0000000000000431.

PMID:
25790042
8.

Use of Monsel solution to treat obstetrical hemorrhage: a review and comparison to other topical hemostatic agents.

Miller DT, Roque DM, Santin AD.

Am J Obstet Gynecol. 2015 Jun;212(6):725-35. doi: 10.1016/j.ajog.2014.12.029. Epub 2015 Jan 8. Review.

9.

Past, present and future targets for immunotherapy in ovarian cancer.

Schwab CL, English DP, Roque DM, Pasternak M, Santin AD.

Immunotherapy. 2014;6(12):1279-93. doi: 10.2217/imt.14.90. Review.

10.

Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.

English DP, Bellone S, Schwab CL, Roque DM, Lopez S, Bortolomai I, Cocco E, Bonazzoli E, Chatterjee S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.

Cancer. 2015 Feb 1;121(3):403-12. doi: 10.1002/cncr.29062. Epub 2014 Sep 23.

11.

Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo.

Schwab CL, English DP, Roque DM, Bellone S, Lopez S, Cocco E, Nicoletti R, Rutherford TJ, Schwartz PE, Santin AD.

Gynecol Oncol. 2014 Oct;135(1):142-8. doi: 10.1016/j.ygyno.2014.08.006. Epub 2014 Aug 12.

PMID:
25124161
12.

Appearances can be deceiving: ovarian mass presents as vaginal prolapse.

Dick-Biascoechea MA, Roque DM, Schwartz PE.

Am J Obstet Gynecol. 2014 Sep;211(3):310.e1-2. doi: 10.1016/j.ajog.2014.05.006. Epub 2014 May 6. No abstract available.

PMID:
24813973
13.

HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges.

Buza N, Roque DM, Santin AD.

Arch Pathol Lab Med. 2014 Mar;138(3):343-50. doi: 10.5858/arpa.2012-0416-RA. Review.

PMID:
24576030
14.

Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Black JD, English DP, Roque DM, Santin AD.

Womens Health (Lond). 2014 Jan;10(1):45-57. doi: 10.2217/whe.13.72. Review.

15.

Taxanes: their impact on gynecologic malignancy.

Schwab CL, English DP, Roque DM, Santin AD.

Anticancer Drugs. 2014 May;25(5):522-35. doi: 10.1097/CAD.0000000000000057. Review.

16.

HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.

English DP, Roque DM, Carrara L, Lopez S, Bellone S, Cocco E, Bortolomai I, Schwartz PE, Rutherford T, Santin AD.

Gynecol Oncol. 2013 Dec;131(3):753-8. doi: 10.1016/j.ygyno.2013.08.033. Epub 2013 Sep 4.

PMID:
24012800
17.

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel.

Roque DM, Buza N, Glasgow M, Bellone S, Bortolomai I, Gasparrini S, Cocco E, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD.

Clin Exp Metastasis. 2014 Jan;31(1):101-10. doi: 10.1007/s10585-013-9614-5. Epub 2013 Sep 5.

18.

Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis.

Bignotti E, Tassi RA, Calza S, Ravaggi A, Rossi E, Donzelli C, Todeschini P, Romani C, Bandiera E, Zanotti L, Carnazza M, Quadraro F, Tognon G, Sartori E, Pecorelli S, Roque DM, Santin AD.

J Transl Med. 2013 Jul 2;11:162. doi: 10.1186/1479-5876-11-162.

19.

Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.

Roque DM, Bellone S, English DP, Buza N, Cocco E, Gasparrini S, Bortolomai I, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD.

Cancer. 2013 Jul 15;119(14):2582-92. doi: 10.1002/cncr.28017. Epub 2013 Apr 12.

20.

Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.

Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD.

Am J Obstet Gynecol. 2013 Jul;209(1):62.e1-9. doi: 10.1016/j.ajog.2013.04.017. Epub 2013 Apr 10.

PMID:
23583215

Supplemental Content

Loading ...
Support Center